{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:18:58Z","timestamp":1788261538371,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Anti-GQ1b antibody syndromes span a clinical continuum from peripheral Guillain-Barr\u00e9 syndrome (GBS) to central Bickerstaff brainstem encephalitis (BBE), but reliable biomarkers of central nervous system (CNS) involvement that could guide treatment intensity are lacking. We report a 37-year-old woman with a relapsing GBS\u2013Miller Fisher syndrome (MFS)\u2013BBE overlap phenotype. In the first episode (March 2024), plasma exchange, intravenous methylprednisolone and IVIG were administered after anti-GD1a IgG was detected. After self-discontinuation of immunotherapy, she was readmitted in May 2024 with a two-month course of progressive weakness acutely worsened over four days, ophthalmoplegia, dysarthria, intermittent choking and bilateral extensor plantar responses. CSF showed albuminocytologic dissociation (protein 2.21 g\/L; total cell count 40\u00d710\n                    <jats:sup>6<\/jats:sup>\n                    \/L with a normal nucleated cell count) together with evidence of intrathecal IgG synthesis (IgG index 1.13; synthesis rate 147.10 mg\/24h; oligoclonal bands type III with homologous serum bands). Electrophysiology revealed an acute motor axonal neuropathy pattern. IVIG and methylprednisolone were administered, with substantial improvement but persistent mild dysarthria and ataxia at three-month follow-up. The diagnosis was based mainly on the clinical course and electrophysiological findings, supported by serology and CSF analysis. This case shows that intrathecal IgG synthesis may complement albuminocytologic dissociation as a marker of CNS involvement in anti-GQ1b syndromes and supports the hypothesis\u2014requiring prospective testing\u2014that CSF immunological profiling could inform treatment intensity.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1794662","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:54:40Z","timestamp":1788260080000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Intrathecal IgG synthesis as a biomarker for CNS involvement in anti-GQ1b antibody syndrome: a case report and hypothesis-generating treatment framework"],"prefix":"10.3389","volume":"17","author":[{"given":"Han","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuming","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0775-0","article-title":"Bickerstaff\u2019s brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases","volume":"255","author":"Ito","year":"2008","journal-title":"J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.70.1.50","article-title":"Anti-GQ1b IgG antibody syndrome: clinical and immunological range","volume":"70","author":"Odaka","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2026.1763283","article-title":"A unified spectrum model for the anti-GQ1b antibody syndromes","volume":"17","author":"El Abdi","year":"2026","journal-title":"Front Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-barr\u00e9 syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome","volume":"7","author":"van Doorn","year":"2008","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063.pub2","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00726","article-title":"The cerebrospinal fluid in multiple sclerosis","volume":"10","author":"Deisenhammer","year":"2019","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-510x(00)00501-3","article-title":"Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs","volume":"184","author":"Reiber","year":"2001","journal-title":"J Neurol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp.57.8.897","article-title":"Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report","volume":"57","author":"Andersson","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jneuroim.2006.07.006","article-title":"Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness","volume":"180","author":"Link","year":"2006","journal-title":"J Neuroimmunol"},{"key":"B13","article-title":"Bickerstaff\u2019s encephalitis","volume":"20","author":"Garc\u00eda-Garc\u00eda","year":"2005","journal-title":"Neurologia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440512","article-title":"Electrophysiological classification of Guillain-Barr\u00e9 syndrome: clinical associations and outcome","volume":"44","author":"Hadden","year":"1998","journal-title":"Ann Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959","article-title":"EAN\/PNS guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001446.pub5","article-title":"Corticosteroids for guillain-barr\u00e9 syndrome","author":"Hughes","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg233","article-title":"Bickerstaff\u2019s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barr\u00e9 syndrome","volume":"126","author":"Odaka","year":"2003","journal-title":"Brain"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000345847","article-title":"A case of Fisher-Bickerstaff syndrome overlapped by Guillain-Barr\u00e9 syndrome","volume":"4","author":"Fujii","year":"2012","journal-title":"Case Rep Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd004761.pub2","article-title":"Treatment for Fisher syndrome, Bickerstaff\u2019s brainstem encephalitis and related disorders","author":"Overell","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3205\/000220","article-title":"Guillain-Barr\u00e9 syndrome: clinical profile and management","volume":"13","author":"Sudulagunta","year":"2015","journal-title":"Ger Med Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000258673.31824.61","article-title":"Intravenous immunoglobulin therapy for Miller Fisher syndrome","volume":"68","author":"Mori","year":"2007","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082337","article-title":"Antibodies to heteromeric glycolipid complexes in Guillain-Barr\u00e9 syndrome","volume":"8","author":"Rinaldi","year":"2013","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2009.171702","article-title":"Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction","volume":"587","author":"Plomp","year":"2009","journal-title":"J Physiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.4401-06.2007","article-title":"Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers","volume":"27","author":"Susuki","year":"2007","journal-title":"J Neurosci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-302312","article-title":"Biology of the blood-nerve barrier and its alteration in immune-mediated neuropathies","volume":"84","author":"Kanda","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1085-9489.2005.0010202.x","article-title":"The immunobiology of Guillain-Barr\u00e9 syndromes","volume":"10","author":"Willison","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"B29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/brain\/118.3.597","article-title":"Guillain-Barr\u00e9 syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies","volume":"118","author":"Ho","year":"1995","journal-title":"Brain"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwp027","article-title":"Antiganglioside antibodies and their pathophysiological effects on Guillain-Barr\u00e9 syndrome and related disorders\u2014a review","volume":"19","author":"Kaida","year":"2009","journal-title":"Glycobiology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(13)70215-1","article-title":"Axonal Guillain-Barr\u00e9 syndrome: concepts and controversies","volume":"12","author":"Kuwabara","year":"2013","journal-title":"Lancet Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf272","article-title":"Peripheral neuropathies and anti-glycolipid antibodies","volume":"125","author":"Willison","year":"2002","journal-title":"Brain"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.6.813","article-title":"Pharmacokinetics of intravenous immunoglobulin: a systematic review","volume":"26","author":"Koleba","year":"2006","journal-title":"Pharmacotherapy"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(78)92644-2","article-title":"Controlled trial of prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7453\/gahmj.2013.008","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"2013","author":"Gagnier","year":"2013","journal-title":"BMJ Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1794662\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:54:41Z","timestamp":1788260081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1794662\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1794662"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1794662","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1794662"}}